In the latest session, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed at $15.2 down -1.36% from its previous closing price of $15.41. In other words, the price has decreased by -$1.36 from its previous closing price. On the day, 0.5 million shares were traded. CNTA stock price reached its highest trading level at $15.695 during the session, while it also had its lowest trading level at $15.18.
Ratios:
For a deeper understanding of Centessa Pharmaceuticals plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.37 and its Current Ratio is at 14.37. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on July 21, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On May 28, 2025, Needham started tracking the stock assigning a Buy rating and target price of $35.
On May 08, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $30.Chardan Capital Markets initiated its Buy rating on May 08, 2025, with a $30 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 25 ’25 when Weinhoff Gregory M sold 10,000 shares for $15.56 per share. The transaction valued at 155,598 led to the insider holds 122,279 shares of the business.
Weinhoff Gregory M bought 10,000 shares of CNTA for $155,598 on Jul 25 ’25. On Jul 21 ’25, another insider, SAHA SAURABH, who serves as the Chief Executive Officer of the company, sold 55,000 shares for $15.92 each. As a result, the insider received 875,600 and left with 221,017 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 2031008768 and an Enterprise Value of 1864496384. For the stock, the TTM Price-to-Sale (P/S) ratio is 134.80 while its Price-to-Book (P/B) ratio in mrq is 5.26. Its current Enterprise Value per Revenue stands at 124.3 whereas that against EBITDA is -9.541.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.48, which has changed by 0.43261075 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $19.09, while it has fallen to a 52-week low of $9.10. The 50-Day Moving Average of the stock is 12.07%, while the 200-Day Moving Average is calculated to be 0.35%.
Shares Statistics:
For the past three months, CNTA has traded an average of 940.50K shares per day and 884540 over the past ten days. A total of 133.55M shares are outstanding, with a floating share count of 85.48M. Insiders hold about 36.00% of the company’s shares, while institutions hold 57.01% stake in the company. Shares short for CNTA as of 1752537600 were 3674823 with a Short Ratio of 3.91, compared to 1749772800 on 4468784. Therefore, it implies a Short% of Shares Outstanding of 3674823 and a Short% of Float of 3.2399999999999998.
Earnings Estimates
The current rating of Centessa Pharmaceuticals plc ADR (CNTA) reflects the combined expertise of 6.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.31 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.22 and -$1.5 for the fiscal current year, implying an average EPS of -$1.33. EPS for the following year is -$1.58, with 7.0 analysts recommending between -$1.34 and -$1.81.
